CERS Projected Dividend Yield

Cerus Corp. ( NASDAQ : CERS )

Cerus is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The INTERCEPT Blood System, which is based on Co.'s technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Co.'s INTERCEPT Blood System is intented for use with blood components including platelets, plasma and red blood cells. Co. has received U.S. Food and Drug Administration approval for the INTERCEPT Blood System for Cryoprecipitation, which uses Co.'s plasma system to produce INTERCEPT Fibrinogen Complex for the treatment and control of bleeding.

20 YEAR PERFORMANCE RESULTS